Most Read

Zavegepant nasal spray is claimed to be the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation for the acute treatment of migraine in

The positive opinion for use of Cosentyx either alone or in combination with methotrexate has been given for the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA)

Proceeds from the financing round will be used by the company to advance Inceptor Bio’s CAR-T lead programme to a Phase I clinical trial as well as continue

This round was led by founding investors Syncona and Mass General Brigham Ventures. With this new funding round, SwanBio has so far raised $133m. SwanBio chair and chief

Grupo Somar is an integrated pharmaceutical company with focus on developing, manufacturing, and marketing branded generic, private label and OTC products aimed at the private market and providing

This multi-year deal builds on the ongoing collaboration with AstraZeneca announced in June last year, to include the development of small molecule inhibitors targeting a second cancer-related epigenetic

Statera Biopharma president and CEO Michael K Handley said: “The strategic partnership with Lay Sciences has the potential to produce near term revenue. “The agreement allows Statera the

Additionally, the FDA’s Division of Neurology I granted its request for a pre-IND meeting for discussing a development path for elamipretide along with products within the approved exon-skipping

The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with